Pub Date : 2023-11-04DOI: 10.32756/0869-5490-2023-4-41-44
E. L. Vartanyan, R.S. Polyakov, L. Dyachuk, D.V. Fetzer, Y. Arutyunova, N.A. Karanadze, M.A. Trukhanova, N. A. Mironov, S.T. Matskeplishvili
To evaluate the impact of fractional flow reserve (FFR) assessment on the choice of the myocardial revascularization strategy in patients with ischemic heart disease and multivessel coronary artery disease and to compare the long-term outcomes of complete functional or anatomical revascularization.
{"title":"Fractional flow reserve assessment for guiding the strategy of endovascular treatment of patients with chronic coronary syndrome and multivessel coronary artery disease","authors":"E. L. Vartanyan, R.S. Polyakov, L. Dyachuk, D.V. Fetzer, Y. Arutyunova, N.A. Karanadze, M.A. Trukhanova, N. A. Mironov, S.T. Matskeplishvili","doi":"10.32756/0869-5490-2023-4-41-44","DOIUrl":"https://doi.org/10.32756/0869-5490-2023-4-41-44","url":null,"abstract":"To evaluate the impact of fractional flow reserve (FFR) assessment on the choice of the myocardial revascularization strategy in patients with ischemic heart disease and multivessel coronary artery disease and to compare the long-term outcomes of complete functional or anatomical revascularization.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"57 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139289502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-04DOI: 10.32756/0869-5490-2023-4-36-40
O. Goncharov, D. Mavani, A. Ledovskikh, L. Tsukurova, M. Gavrik, I. Balaban, A. Globenko, A. Kapashin, M. Pasko
To determine the optimal dosing of Ranquilon® (N-(6-phenylhexanoyl)-glycyl-L-tryptophan amide) tablets (Valenta Pharm JSC) for the treatment of patients with anxiety associated with neurasthenia and adjustment disorders.
{"title":"Optimal dosage regimen of Ranquilon® for patients with anxiety associated with neurasthenia and adaptation disorders: phase II clinical trial","authors":"O. Goncharov, D. Mavani, A. Ledovskikh, L. Tsukurova, M. Gavrik, I. Balaban, A. Globenko, A. Kapashin, M. Pasko","doi":"10.32756/0869-5490-2023-4-36-40","DOIUrl":"https://doi.org/10.32756/0869-5490-2023-4-36-40","url":null,"abstract":"To determine the optimal dosing of Ranquilon® (N-(6-phenylhexanoyl)-glycyl-L-tryptophan amide) tablets (Valenta Pharm JSC) for the treatment of patients with anxiety associated with neurasthenia and adjustment disorders.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"9 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139289434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-04DOI: 10.32756/0869-5490-2023-4-77-80
А. Fedorenko, A. Burbello, D.A. Sychev, M. Pokladova
To determine the rationale for implementation of clinical pharmacology consultation into the Russian obligatory medical insurance system.
确定在俄罗斯强制性医疗保险制度中实施临床药理学咨询的理由。
{"title":"Implementation of clinical pharmacology consultation into the obligatory medical insurance system","authors":"А. Fedorenko, A. Burbello, D.A. Sychev, M. Pokladova","doi":"10.32756/0869-5490-2023-4-77-80","DOIUrl":"https://doi.org/10.32756/0869-5490-2023-4-77-80","url":null,"abstract":"To determine the rationale for implementation of clinical pharmacology consultation into the Russian obligatory medical insurance system.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"22 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139289442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-04DOI: 10.32756/0869-5490-2023-4-45-50
P. Kakhsurueva, E. Kamyshova, I.N. Bobkova, E. Andreeva, O.A. Li
To evaluate the significance of circulating antibodies to the M-type phospholipase A2 receptor (anti-PLA2R) in the diagnosis of primary membranous nephropathy (MN) and the determination of the clinical features of the disease.
评估 M 型磷脂酶 A2 受体循环抗体（抗 PLA2R）在诊断原发性膜性肾病（MN）和确定该病临床特征方面的意义。
{"title":"Clinical significance of antibodies to the M-type phospholipase A2 receptor in patients with primary membranous nephropathy","authors":"P. Kakhsurueva, E. Kamyshova, I.N. Bobkova, E. Andreeva, O.A. Li","doi":"10.32756/0869-5490-2023-4-45-50","DOIUrl":"https://doi.org/10.32756/0869-5490-2023-4-45-50","url":null,"abstract":"To evaluate the significance of circulating antibodies to the M-type phospholipase A2 receptor (anti-PLA2R) in the diagnosis of primary membranous nephropathy (MN) and the determination of the clinical features of the disease.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"9 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139289593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The use of real-world data (RWD) and real-world evidence (RWE) is an international trend in the modern healthcare system. In a review article, the authors highlight the use of RWD/RWE for drug development in the following categories: drug-drug interactions; dose selection in special populations such as patients with elimination organ dysfunction; dosing optimization in children; the use of quantitative clinical pharmacology in model-based drug development; use of RWE as a parallel data source to complement a randomized controlled trial to extend indications; RWD/RWE to create an external control group for rare diseases.
{"title":"Use of real-world data for drug development","authors":"A.S. Kolbin, R.R. Niyazov, V.V. Kalinichenko, S.V. Glagolev","doi":"10.32756/0869-5490-2023-4-16-23","DOIUrl":"https://doi.org/10.32756/0869-5490-2023-4-16-23","url":null,"abstract":"The use of real-world data (RWD) and real-world evidence (RWE) is an international trend in the modern healthcare system. In a review article, the authors highlight the use of RWD/RWE for drug development in the following categories: drug-drug interactions; dose selection in special populations such as patients with elimination organ dysfunction; dosing optimization in children; the use of quantitative clinical pharmacology in model-based drug development; use of RWE as a parallel data source to complement a randomized controlled trial to extend indications; RWD/RWE to create an external control group for rare diseases.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139289399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-04DOI: 10.32756/0869-5490-2023-4-58-63
E. Tao, A. Moiseev, N. Bulanov, V. Sholomova, S. Moiseev
To evaluate survival among patients with Fabry disease (FD) depending on the type of renal replacement therapy and to investigate the efficacy of dialysis screening in the early diagnosis of FD in relatives of probands.
{"title":"Chronic renal failure in Fabry disease: the long-term survival on renal replacement therapy","authors":"E. Tao, A. Moiseev, N. Bulanov, V. Sholomova, S. Moiseev","doi":"10.32756/0869-5490-2023-4-58-63","DOIUrl":"https://doi.org/10.32756/0869-5490-2023-4-58-63","url":null,"abstract":"To evaluate survival among patients with Fabry disease (FD) depending on the type of renal replacement therapy and to investigate the efficacy of dialysis screening in the early diagnosis of FD in relatives of probands.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"22 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139289530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-04DOI: 10.32756/0869-5490-2023-4-5-15
S. Moiseev, I.N. Bobkova, N. Chebotareva, N. Bulanov
Nephrotic syndrome (NS), characterized by proteinuria >3.5 g daily and hypoalbuminemia (± oedema and dyslipidemia) is one of the leading manifestations of various glomerular diseases, both primary and secondary (systemic autoimmune diseases, diabetes mellitus, amyloidosis, monoclonal gammapathy, malignancy, infections, drugs, etc). Kidney biopsy is usually required to establish the cause of NS in adult patients and to choose optimal treatment. In a review article, the authors discuss the most common ethiological factors of NS and its differential diagnosis.
{"title":"Nephrotic syndrome: ethiological factors and differential diagnosis","authors":"S. Moiseev, I.N. Bobkova, N. Chebotareva, N. Bulanov","doi":"10.32756/0869-5490-2023-4-5-15","DOIUrl":"https://doi.org/10.32756/0869-5490-2023-4-5-15","url":null,"abstract":"Nephrotic syndrome (NS), characterized by proteinuria >3.5 g daily and hypoalbuminemia (± oedema and dyslipidemia) is one of the leading manifestations of various glomerular diseases, both primary and secondary (systemic autoimmune diseases, diabetes mellitus, amyloidosis, monoclonal gammapathy, malignancy, infections, drugs, etc). Kidney biopsy is usually required to establish the cause of NS in adult patients and to choose optimal treatment. In a review article, the authors discuss the most common ethiological factors of NS and its differential diagnosis.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"87 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139289455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-04DOI: 10.32756/0869-5490-2023-4-64-72
S. Moiseev, N. Chebotareva, A. Moiseev, P. Novikov, V. Sholomova
Hypophosphatasia (HPP) is a rare hereditary disease characterized by reduced activity of tissue-nonspecific alkaline phosphatase (TNSALP) encoded by ALPL gene, defective mineralization of bone (osteomalacia) and various musculoskeletal manifestations, such as bone deformity, teeth loss, recurrent fractures, chronic bone and muscle pain, reduced muscular strength, etc. Deficiency of TNSALP activity leads to the extracellular accumulation of its substrates, including inorganic pyrophosphate that inhibits bone mineralization. Homozygous and compound heterozygous mutations of the ALPL gene are associated with a lower TNSALP activity and HPP severity. However, heterozygous dominant negative variants can also result in clinical manifestations. The authors present two adult patients with HPP and discuss diverse clinical features of the disease and the efficacy of asfotase alpha, the human recombinant enzyme-replacement therapy that replaces deficient TNSALP. In adults and adolescents with pediatric-onset HPP, treatment with asfotase alfa was associated with improved functional abilities and health-related quality of life.
{"title":"Hypophosphatasia in adults: how not to overlook a rare disease?","authors":"S. Moiseev, N. Chebotareva, A. Moiseev, P. Novikov, V. Sholomova","doi":"10.32756/0869-5490-2023-4-64-72","DOIUrl":"https://doi.org/10.32756/0869-5490-2023-4-64-72","url":null,"abstract":"Hypophosphatasia (HPP) is a rare hereditary disease characterized by reduced activity of tissue-nonspecific alkaline phosphatase (TNSALP) encoded by ALPL gene, defective mineralization of bone (osteomalacia) and various musculoskeletal manifestations, such as bone deformity, teeth loss, recurrent fractures, chronic bone and muscle pain, reduced muscular strength, etc. Deficiency of TNSALP activity leads to the extracellular accumulation of its substrates, including inorganic pyrophosphate that inhibits bone mineralization. Homozygous and compound heterozygous mutations of the ALPL gene are associated with a lower TNSALP activity and HPP severity. However, heterozygous dominant negative variants can also result in clinical manifestations. The authors present two adult patients with HPP and discuss diverse clinical features of the disease and the efficacy of asfotase alpha, the human recombinant enzyme-replacement therapy that replaces deficient TNSALP. In adults and adolescents with pediatric-onset HPP, treatment with asfotase alfa was associated with improved functional abilities and health-related quality of life.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"148 5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139289492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-04DOI: 10.32756/0869-5490-2023-4-51-57
V. A. Tretyakova, O. V. Ermilov, P. K. Alferov
To evaluate the features of ST-segment elevation myocardial infarction (STEMI) in patients with two types of metabolic-associated fatty liver disease (MAFLD), that is, liver steatosis (LS) and steatohepatitis (SH).
目的：评估两种代谢相关性脂肪肝（MAFLD）（即肝脂肪变性（LS）和脂肪性肝炎（SH））患者 ST 段抬高型心肌梗死（STEMI）的特征。
{"title":"Features of myocardial infarction with ST segment elevation in patients with non-alcoholic liver steatosis and steatohepatitis","authors":"V. A. Tretyakova, O. V. Ermilov, P. K. Alferov","doi":"10.32756/0869-5490-2023-4-51-57","DOIUrl":"https://doi.org/10.32756/0869-5490-2023-4-51-57","url":null,"abstract":"To evaluate the features of ST-segment elevation myocardial infarction (STEMI) in patients with two types of metabolic-associated fatty liver disease (MAFLD), that is, liver steatosis (LS) and steatohepatitis (SH).","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"13 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139289533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-04DOI: 10.32756/0869-5490-2023-4-30-35
Z. Kobalava, A. Lapshin, S. Galochkin
To evaluate prognosis of hospitalized patients with decompensated heart failure (HF) and iron deficiency (ID) and the changes in ID occurrence without iron supplementation.
{"title":"Prognostic value of various iron deficiency criteria in patients with decompensated heart failure","authors":"Z. Kobalava, A. Lapshin, S. Galochkin","doi":"10.32756/0869-5490-2023-4-30-35","DOIUrl":"https://doi.org/10.32756/0869-5490-2023-4-30-35","url":null,"abstract":"To evaluate prognosis of hospitalized patients with decompensated heart failure (HF) and iron deficiency (ID) and the changes in ID occurrence without iron supplementation.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139289443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：